Litcius/Paper detail

Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity

Shuo Wang, An Song, Jun Xie, Yuanyuan Wang, Wenda Wang, Mengjie Zhang, Zhi‐Zhong Wu, Qi‐Chao Yang, Hao Li, Junjie Zhang, Zhi‐Jun Sun

2024Nature Communications78 citationsDOIOpen Access PDF

Abstract

Oncolytic viruses (OVs) show promise as a cancer treatment by selectively replicating in tumor cells and promoting antitumor immunity. However, the current immunogenicity induced by OVs for tumor treatment is relatively weak, necessitating a thorough investigation of the mechanisms underlying its induction of antitumor immunity. Here, we show that HSV-1-based OVs (oHSVs) trigger ZBP1-mediated PANoptosis (a unique innate immune inflammatory cell death modality), resulting in augmented antitumor immune effects. Mechanistically, oHSV enhances the expression of interferon-stimulated genes, leading to the accumulation of endogenous Z-RNA and subsequent activation of ZBP1. To further enhance the antitumor potential of oHSV, we conduct a screening and identify Fusobacterium nucleatum outer membrane vesicle (Fn-OMV) that can increase the expression of PANoptosis execution proteins. The combination of Fn-OMV and oHSV demonstrates potent antitumor immunogenicity. Taken together, our study provides a deeper understanding of oHSV-induced antitumor immunity, and demonstrates a promising strategy that combines oHSV with Fn-OMV.

Topics & Concepts

Oncolytic virusImmunityVirologyBiologyImmune systemImmunologyVirusInflammasome and immune disordersToxoplasma gondii Research Studiesinterferon and immune responses